Pramipexole
| Evidence Level: L4 | Predicted Indications: 10 |
Table of Contents
- Pramipexole
- Pramipexole: From Parkinson's Disease and Restless Legs Syndrome to Attention Deficit-Hyperactivity Disorder
Pramipexole: From Parkinson's Disease and Restless Legs Syndrome to Attention Deficit-Hyperactivity Disorder
One-Sentence Summary
Pramipexole is a dopamine agonist originally used to treat Parkinson's disease and restless legs syndrome. The TxGNN model predicts it may be effective for attention deficit-hyperactivity disorder (ADHD), but there are 0 registered clinical trials and only 7 loosely related publications for this indication, none of them an ADHD trial of pramipexole. The evidence is indirect only.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Parkinson's disease, restless legs syndrome (plus several rare hereditary parkinsonian syndromes) |
| Predicted New Indication | Attention deficit-hyperactivity disorder |
| TxGNN Prediction Score | 99.998% |
| Evidence Level | L4 |
| New Zealand Market Status | Cancelled only (no currently valid authorization) |
| Number of Authorizations | 2 (both cancelled) |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Pramipexole is a non-ergoline dopamine agonist that acts on the D2 and D3 dopamine receptors, with a preference for D3. Detailed mechanism-of-action text is not available in the data compiled for this report, but the receptor-target data confirm this D2/D3 activity.
Parkinson's disease and restless legs syndrome both involve dopaminergic signalling problems. Dopamine dysregulation is also widely implicated in ADHD. Genetic variants of the dopamine D4 receptor and the α2A adrenoceptor have been linked to ADHD, which gives the prediction a plausible mechanistic basis.
However, the link is indirect. No ADHD-specific trial of pramipexole is available. The retrieved literature is mostly off-target: restless legs syndrome reviews, single case reports, a study of a different drug (piribedil), and a receptor-biology study. The only pramipexole RCT in the set tested Tourette's syndrome, a related neurodevelopmental condition, not ADHD.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 22407510 | 2012 | RCT (Tourette's syndrome, not ADHD) | Movement Disorders | Multicenter placebo-controlled trial of pramipexole in Tourette's syndrome, based on the theory that dopamine agonists may normalize dopamine hypersensitivity |
| 19412489 | 2006 | Review | Neuropsychiatric Disease and Treatment | Pramipexole's D3 selectivity and potential use in restless legs syndrome |
| 18656214 | 2008 | Review | Revue Neurologique | Review of restless legs syndrome (relevant to the original indication, not to ADHD) |
| 24992083 | 2014 | Clinical study (different drug: piribedil) | Clinical Neuropharmacology | 11-week comparison of piribedil against pramipexole and ropinirole on vigilance in Parkinson's patients with daytime sleepiness |
| 34182128 | 2021 | Preclinical/in vitro | Pharmacological Research | Dopamine D4 receptor variants and α2A adrenoceptor heteromers, relevant to ADHD and impulse-control disorders |
| 37342213 | 2023 | Case report | Frontiers in Pain Research | Remission of chronic low back pain and oral dysesthesia in a patient with comorbid ADHD, treated with atomoxetine and pramipexole |
| 38649244 | 2024 | Case report | BMJ Case Reports | Hypokalaemia from excessive cola consumption in a patient with ADHD who was taking pramipexole; not evidence of efficacy |
New Zealand Market Information
| Authorization Number | Product Name | Dosage Form | Status |
|---|---|---|---|
| 2450534 | Ramipex | Tab 0.25 mg | Cancelled |
| 2450542 | Ramipex | Tab 1 mg | Cancelled |
Both authorizations are cancelled, so there is currently no valid marketed pramipexole product in New Zealand according to the data compiled for this report.
Safety Considerations
- Disease associations flagged in the knowledge graph (not label text): The drug-disease contraindication links in the knowledge graph include orthostatic hypotension, multiple system atrophy, drug-induced dyskinesia, kidney disease, psychotic disorders (including schizoaffective and schizophreniform disorders), mental disorder, melanoma, sleep apnea syndromes, narcolepsy, and central nervous system disease. These need confirmation against the official product information.
- Drug interactions: The interaction query returned only pharmacological target records (dopamine D2 and D3 receptors), not specific drug-drug interactions.
Please refer to the package insert for authoritative warnings and contraindications.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction score is high, but no ADHD trial exists and the literature is indirect. The only pramipexole RCT in the set targets Tourette's syndrome. No pramipexole product is currently authorized in New Zealand. The mechanistic rationale is plausible but unproven.
To proceed, the following is needed:
- Package insert warnings and contraindications (currently missing, and a blocker for safety screening)
- Detailed mechanism-of-action data
- ADHD-specific preclinical or clinical evidence for pramipexole, such as a pilot trial
- Review of whether the dopaminergic safety profile (impulse-control problems, sleepiness, orthostatic hypotension) is acceptable in an ADHD population
- Clarification of the regulatory pathway, since both New Zealand authorizations are cancelled
Among the other predicted indications for this drug, schizophrenia has considerably stronger evidence than ADHD: a Phase 3 add-on trial (NCT01320982, status unknown) and a published add-on RCT from 2022. It may deserve a separate evaluation.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.